AZADINE AZACITIDINE INJECTION

Get a Price/Quote

AZADINE AZACITIDINE INJECTION Specification

Indication
Treatment of myelodysplastic syndromes (MDS) including refractory anemia, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML)

Dosage Form
Injection

Pacakaging (Quantity Per Box)
1 vial per box

Salt Composition
Azacitidine 100 mg/vial

Origin of Medicine
Imported

Drug Type
Prescription only

Ingredients
Azacitidine

Physical Form
Lyophilized Powder for Injection

Function

Recommended For
Patients with myelodysplastic syndromes

Dosage
As directed by the physician

Dosage Guidelines
Administer via subcutaneous or intravenous route as per medical direction

Suitable For
Adults

Quantity
1 vial

Storage Instructions
Store below 25C, protect from light

Strength
100 mg/vial

Route of Administration
Subcutaneous or Intravenous Injection

Therapeutic Class
Anticancer

Regulatory Approval
US FDA, WHO GMP Certified

Generic Name
Azacitidine

Expiry
24 months from the date of manufacturing

Caution
To be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents

Colour
White to off-white powder

Reconstitution
To be reconstituted with sterile water for injection

AZADINE AZACITIDINE INJECTION Trade Information

Packaging Details
PACK OF 1 VIAL

About AZADINE AZACITIDINE INJECTION

Specifications:-

Brand Name : AZADINE
Content : Azacitidine
strength : 100 mg
Form : Injection
Packing : pack 1 vial
Manufactured By : INTAS

Note : - AZADINE Is A Prescription Drug And Should Be Used Under Proper Medical Guidance And Advice. Do Not Share The Medicine With Others, Since They May Be Suffering From A Problem That Is Not Effectively Treated By This Drug.............

How AZADINE Azacitidine Injection Works

AZADINE contains azacitidine, a cytotoxic agent that interferes with the growth of abnormal blood cells in the bone marrow. By inhibiting DNA methylation, it helps restore normal function to bone marrow cells, thereby improving blood counts in patients with myelodysplastic syndromes and certain leukemias.

Usage and Administration

AZADINE is administered either as a subcutaneous or intravenous injection, according to the physicians specific directions. The injection must be reconstituted with sterile water before use and should always be administered by healthcare professionals experienced in cancer chemotherapy. Proper dosage and protocol will depend on the patients condition and laboratory assessment.

Storage and Handling Instructions

To ensure optimal efficacy and safety, store AZADINE below 25C and keep it out of direct light. The reconstituted solution should be prepared just before administration. Each vial is supplied as a single use and must be discarded if not used within the recommended timeframe.

FAQs of AZADINE AZACITIDINE INJECTION:

Q: How is AZADINE Azacitidine Injection prepared and administered?

A: AZADINE comes as a white to off-white lyophilized powder, which must be reconstituted with sterile water for injection. Administration is performed subcutaneously or intravenously as directed by a qualified physician. Dosage and frequency are tailored to individual patient needs, based on clinical judgment and laboratory tests.

Q: What conditions is AZADINE Azacitidine Injection used to treat?

A: AZADINE is primarily indicated for the treatment of myelodysplastic syndromes, including refractory anemia, chronic myelomonocytic leukemia, and certain cases of acute myeloid leukemia (AML), as prescribed by a healthcare professional.

Q: When should I receive AZADINE Azacitidine Injection?

A: The timing and frequency of AZADINE administration are determined by your oncologist, typically in treatment cycles. Your physician will decide on the schedule after evaluating your diagnosis, disease progression, and overall health.

Q: Where should AZADINE Azacitidine Injection be administered?

A: AZADINE must be administered in a healthcare facility or hospital setting by qualified medical staff experienced in handling anticancer agents, ensuring appropriate monitoring and management of possible side effects.

Q: What are the benefits of AZADINE Azacitidine Injection for patients with myelodysplastic syndromes?

A: AZADINE can improve blood cell counts, reduce the need for transfusions, and control disease progression in patients with myelodysplastic syndromes, offering meaningful support to quality of life and potentially prolonging survival.

Q: What precautions should be taken during the use of AZADINE?

A: AZADINE should only be used under medical supervision. It is not suitable for self-administration and requires careful reconstitution and handling. Regular blood tests are necessary to monitor response and manage any adverse effects.

Tell us about your requirement